Cardiac amyloidosis: Evolving approach to diagnosis and management

Current Treatment Options in Cardiovascular Medicine

Volumn 13, Issue 6, 2011, Pages 528-542

  Meier Ewert, Hans K ^a   Sanchorawala, Vaishali ^a   Berk, John L ^a   Ruberg, Frederick L ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; BIOLOGICAL MARKER; BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; DEXAMETHASONE; DIFLUNISAL; DIURETIC AGENT; FLUDROCORTISONE; LENALIDOMIDE; MELPHALAN; METOPROLOL; MIDODRINE; PREALBUMIN; TAFAMIDIS; THALIDOMIDE; TROPONIN I; TROPONIN T; WARFARIN;

ALLERGIC PNEUMONITIS; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; BRADYCARDIA; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CONSTIPATION; DEFIBRILLATION; DEVICE INFECTION; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FATIGUE; FLUID RETENTION; HAIR LOSS; HEART AMYLOIDOSIS; HEART ARRHYTHMIA; HEART FAILURE; HEMATOMA; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOTENSION; HYPOTHYROIDISM; INFECTION; KIDNEY PERFUSION; LIGHT CHAIN; LUNG FIBROSIS; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PNEUMOTHORAX; PROGNOSIS; PROTEIN VARIANT; QT PROLONGATION; RASH; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; URINE RETENTION;

EID: 81155139089     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-011-0147-4     Document Type: Article

References (51)

1. G Merlini V Bellotti 2003 Molecular mechanisms of amyloidosis N Engl J Med 349 583 596 12904524 10.1056/NEJMra023144 1:CAS:528:DC%2BD3sXmtFCmsbk%3D (Pubitemid 36951371)
2. RA Kyle A Linos CM Beard, et al. 1992 Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 Blood 79 1817 1822 1558973 1:STN:280:DyaK383hs1SqsQ%3D%3D
3. LH Connors A Lim T Prokaeva, et al. 2003 Tabulation of human transthyretin (TTR) variants, 2003 Amyloid 10 160 184 14640030 10.3109/13506120308998998 1:CAS:528:DC%2BD3sXpvFSgsr4%3D (Pubitemid 37372400)
4. DR Jacobson RD Pastore R Yaghoubian, et al. 1997 Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans N Engl J Med 336 466 473 9017939 10.1056/NEJM199702133360703 1:STN:280:DyaK2s7mtV2htg%3D%3D (Pubitemid 27074357)
5. McKinnon, J. The Black Population in the United States: March 2002. US Census Bureau, Washington, D.C. Current Population Reports 2003, Series P20-541.
6. J Buxbaum A Alexander J Koziol, et al. 2010 Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies Am Heart J 159 864 870 20435197 10.1016/j.ahj.2010.02.006 1:CAS:528:DC%2BC3cXlsVOhu7o%3D
7. LH Connors T Prokaeva A Lim, et al. 2009 Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis Am Heart J 158 607 614 19781421 10.1016/j.ahj.2009.08.006 1:CAS:528:DC%2BD1MXhtFyjsrrO
8. C Rapezzi CC Quarta L Riva, et al. 2010 Transthyretin-related amyloidoses and the heart: a clinical overview Nat Rev Cardiol 7 398 408 20479782 10.1038/nrcardio.2010.67 1:CAS:528:DC%2BC3cXnvFylurc%3D
9. M Tanskanen T Peuralinna T Polvikoski, et al. 2008 Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study Ann Med 40 232 239 18382889 10.1080/07853890701842988 1:CAS:528:DC%2BD1cXkt1Smtrs%3D (Pubitemid 351482541)
10. LM Dember PN Hawkins BP Hazenberg, et al. 2007 Eprodisate for the treatment of renal disease in AA amyloidosis N Engl J Med 356 2349 2360 17554116 10.1056/NEJMoa065644 1:CAS:528:DC%2BD2sXmt1Wguro%3D (Pubitemid 46883769)
11. B Murtagh SC Hammill MA Gertz, et al. 2005 Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement Am J Cardiol 95 535 537 15695149 10.1016/j.amjcard.2004.10.028 (Pubitemid 40247559)
12. C Rapezzi G Merlini CC Quarta, et al. 2009 Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types Circulation 120 1203 1212 19752327 10.1161/CIRCULATIONAHA.108.843334 1:CAS:528:DC%2BD1MXhtFGjsrbM This detailed characterization of electrocardiographic, echocardiographic, and hemodynamic findings and outcome of cardiac amyloidosis due to AL or TTR amyloid is the largest collection of subjects reported to date.
13. A Biolo S Ramamurthy LH Connors, et al. 2008 Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition Circ Heart Fail 1 249 257 19808299 10.1161/CIRCHEARTFAILURE.108.788687 1:CAS:528: DC%2BD1cXhtlGmtbjO
14. DA Brenner M Jain DR Pimentel, et al. 2004 Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress Circ Res 94 1008 1010 15044325 10.1161/01.RES.0000126569.75419.74 1:CAS:528:DC%2BD2cXjt1ylu7c%3D (Pubitemid 38579694)
15. B Ng LH Connors R Davidoff, et al. 2005 Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis Arch Intern Med 165 1425 1429 15983293 10.1001/archinte.165.12.1425 (Pubitemid 40973426)
16. A Dispenzieri MA Gertz RA Kyle, et al. 2004 Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood 104 1881 1887 15044258 10.1182/blood-2004-01-0390 1:CAS:528:DC%2BD2cXns1Oku78%3D (Pubitemid 39202301)
17. AV Kristen E Giannitsis S Lehrke, et al. 2010 Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay Blood 116 2455 2461 20581312 10.1182/blood-2010-02-267708 1:CAS:528:DC%2BC3cXhtlyqt7nK
18. G Palladini C Campana C Klersy, et al. 2003 Serum N-Terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis Circulation 107 2440 2445 12719281 10.1161/01.CIR.0000068314.02595. B2 1:CAS:528:DC%2BD3sXjs1antLk%3D (Pubitemid 36605226)
19. RQ Migrino RK Mareedu D Eastwood, et al. 2009 Left ventricular ejection time on echocardiography predicts long-term mortality in light chain amyloidosis J Am Soc Echocardiogr 22 1396 1402 19880277 10.1016/j.echo.2009.09.012
20. J Koyama RH Falk 2010 Prognostic significance of strain Doppler imaging in light-chain amyloidosis JACC Cardiovasc Imaging 3 333 342 20394893 10.1016/j.jcmg.2009.11.013
21. D Bellavia PA Pellikka GB Al-Zahrani, et al. 2010 Independent predictors of survival in primary systemic (AL) Amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study J Am Soc Echocardiogr 23 643 652 20434879 10.1016/j.echo.2010.03.027
22. AM Maceira J Joshi SK Prasad, et al. 2005 Cardiovascular magnetic resonance in cardiac amyloidosis Circulation 111 195 202 10.1161/01.CIR. 0000152819.97857.9D (Pubitemid 40139730)
23. FL Ruberg E Appelbaum R Davidoff, et al. 2009 Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis Am J Cardiol 103 544 549 19195518 10.1016/j.amjcard.2008.09.105
24. H Vogelsberg H Mahrholdt CC Deluigi, et al. 2008 Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: Noninvasive imaging compared to endomyocardial biopsy J Am Coll Cardiol 51 1022 1030 18325442 10.1016/j.jacc.2007.10.049 (Pubitemid 351318125)
25. IS Syed JF Glockner D Feng, et al. 2010 Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis JACC Cardiovasc Imaging 3 155 164 20159642 10.1016/j.jcmg.2009.09.023
26. BA Austin WH Tang ER Rodriguez, et al. 2009 Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis JACC Cardiovasc Imaging 2 1369 1377 20083070 10.1016/j.jcmg.2009.08.008
27. A Maceira S Prasad P Hawkins, et al. 2008 Cardiovascular Magnetic Resonance and prognosis in cardiac amyloidosis J Cardiovasc Magn Reson 10 54 66 19032744 10.1186/1532-429X-10-54
28. A Glaudemans R Slart C Zeebregts, et al. 2009 Nuclear imaging in cardiac amyloidosis Eur J Nucl Med Mol Imaging 36 702 714 19156411 10.1007/s00259-008- 1037-1 1:STN:280:DC%2BD1M7pvVGhsQ%3D%3D
29. E Perugini PL Guidalotti F Salvi, et al. 2005 Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-Diphosphono-1,2- propanodicarboxylic acid scintigraphy J Am Coll Cardiol 46 1076 1084 16168294 10.1016/j.jacc.2005.05.073 (Pubitemid 41316518)
30. M Hongo K Urushibata R Kai, et al. 2002 Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis Am Heart J 144 122 129 12094198 10.1067/mhj.2002.123115 1:CAS:528:DC%2BD38XlvFyqs7c%3D (Pubitemid 34734765)
31. BP Hazenberg MH van Rijswijk DA Piers, et al. 2006 Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis Am J Med 119 355.e15 355.e24 10.1016/j.amjmed.2005.08.043
32. Tsai SB, Seldin DC, Wu H, et al. Myocardial infarction with "clean coronaries" caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid 2011 (in press).
33. RH Falk RL Comenzo M Skinner 1997 The systemic amyloidoses N Engl J Med 337 898 909 9302305 10.1056/NEJM199709253371306 1:STN:280:DyaK2svjtlSjuw%3D%3D (Pubitemid 27408573)
34. SW Dubrey K Cha J Anderson, et al. 1998 The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement Q J Med 91 141 157 10.1093/qjmed/91.2.141 1:STN:280:DyaK1c3ktVSntg%3D%3D (Pubitemid 28102667)
35. A Rubinow M Skinner AS Cohen 1981 Digoxin sensitivity in amyloid cardiomyopathy Circulation 63 1285 1288 7014028 10.1161/01.CIR.63.6.1285 1:STN:280:DyaL3M7os1Oiuw%3D%3D (Pubitemid 11120664)
36. MA Gertz RH Falk M Skinner, et al. 1985 Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents Am J Cardiol 55 1645 4003314 10.1016/0002-9149(85)90995-6 1:STN:280: DyaL2M3it1antg%3D%3D (Pubitemid 15059308)
37. SS Dhruva RF Redberg 2010 Accelerated approval and possible withdrawal of midodrine JAMA 304 2172 2173 21081731 10.1001/jama.2010.1695 1:CAS:528:DC%2BC3cXhsVyktL7F
38. D Feng WD Edwards JK Oh, et al. 2007 Intracardiac thrombosis and embolism in patients with cardiac amyloidosis Circulation 116 2420 2426 17984380 10.1161/CIRCULATIONAHA.107.697763 (Pubitemid 350145076)
39. D Feng IS Syed M Martinez, et al. 2009 Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis Circulation 119 2490 2497 19414641 10.1161/CIRCULATIONAHA.108.785014 1:CAS:528:DC%2BD1MXls1Gks70%3D This report emphasizes the high risk of cardiac thromboembolism in cardiac amyloidosis and shows that impaired diastolic function correlates with the prevalence of intra-cardiac thrombosis. The authors recommend that anticoagulation therapy be carefully considered in patients with cardiac amyloidosis and severe diastolic impairment.
40. SJ Connolly MD Ezekowitz S Yusuf, et al. 2009 Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 1139 1151 19717844 10.1056/NEJMoa0905561 1:CAS:528:DC%2BD1MXhtFOjsLnN
41. V Sanchorawala M Skinner K Quillen, et al. 2007 Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation Blood 110 3561 3563 17673601 10.1182/blood-2007-07-099481 1:CAS:528:DC%2BD2sXhtlarur3L (Pubitemid 350159622)
42. A Jaccard P Moreau V Leblond, et al. 2007 High-Dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 357 1083 1093 17855669 10.1056/NEJMoa070484 1:CAS:528:DC%2BD2sXhtVGqt7rF (Pubitemid 47443213)
43. A Dispenzieri MQ Lacy SR Zeldenrust, et al. 2007 The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis Blood 109 465 470 17008538 10.1182/blood-2006-07-032987 1:CAS:528:DC%2BD2sXivVykur0%3D (Pubitemid 46105939)
44. DE Reece V Sanchorawala U Hegenbart, et al. 2009 Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study Blood 114 1489 1497 19498019 10.1182/blood-2009-02-203398 1:CAS:528:DC%2BD1MXhtVyiur3N
45. M Skinner V Sanchorawala DC Seldin, et al. 2004 High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study Ann Intern Med 140 85 93 14734330 1:CAS:528:DC%2BD2cXht1WgsL0%3D
46. AV Kristen JB Perz SO Schonland, et al. 2007 Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis J Heart Lung Transplant 26 1313 1319 18096484 10.1016/j.healun.2007.09.014 (Pubitemid 350256989)
47. (Meier-Ewert HK, Sanchorawala V, Berk J, et al. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis. Amyloid 2011;18 Suppl 1:125-26.
48. AV Kristen TJ Dengler U Hegenbart, et al. 2008 Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death Heart Rhythm 5 235 240 18242546 10.1016/j.hrthm.2007.10.016
49. BR Dey SS Chung TR Spitzer, et al. 2010 Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure Transplantation 90 905 911 20733534 10.1097/TP.0b013e3181f10edb 1:CAS:528:DC%2BC3cXhtlSqu73P This report illustrates that carefully selected patients with light chain amyloidosis who are ineligible for HDM/SCT due to isolated advanced cardiac involvement can be treated sequentially with cardiac transplantation and then HDM/SCT. Among patients that received both therapies, long-term survival was comparable to that of cardiac transplant recipients with other diseases.
50. E Pilato A Dell'Amore L Botta, et al. 2007 Combined heart and liver transplantation for familial amyloidotic neuropathy Eur J Cardiothorac Surg 32 180 182 17449267 10.1016/j.ejcts.2007.03.023 (Pubitemid 46874959)
51. P Hammarstrom RL Wiseman ET Powers, et al. 2003 Prevention of transthyretin amyloid disease by changing protein misfolding energetics Science 299 713 716 12560553 10.1126/science.1079589 (Pubitemid 36159487)